Objective: To evaluate the efficacy of transanal excision (TAE) combined with radiotherapy for rectal adenocarcinoma, assess the ability of pretreatment endoscopic ultrasound (EUS) to predict failures, and determine the prognostic value of downstaging and complete pathological response.
patients cannot tolerate the surgery, or they refuse it due to the possibility of permanent colostomy and other complications. In these cases, a reasonable treatment alternative to prevent patient morbidity or to satisfy patient requests to avoid permanent colostomy is needed.
A few small, published series have shown that preoperative chemoradiation can effectively downstage selected T2 and T3 rectal lesions that might have required abdominoperineal resection (APR) so that they can be subsequently excised and managed by TAE, thereby preserving sphincter function. [2] [3] [4] [5] Postoperative chemoradiotherapy is a reasonable option for patients who were thought to have T1 lesions, but then on pathology, had either a higher stage lesion or unfavorable histology. 6 NCCN guidelines currently recommend abdominal surgery for these patients, but patients might decline this option for a number of reasons. The purpose of this study was to report the outcomes of patients with rectal adenocarcinoma treated with radiation therapy and TAE at the University of Florida between July 1998 and March 2008. Additionally,
we assessed the power of endoscopic ultrasound (EUS) staging, pathologic downstaging, and pathological response for predicting local recurrence and distant metastasis.
Methods
Under an institutional review board-approved protocol, we reviewed the medical records of 38 patients treated with preoperative or postoperative radiation and TAE for rectal adenocarcinoma Radiotherapy treatment typically was delivered using 18-MV photons on the lateral and anterior portals and 6-MV photons for the posterior field. The dose was specified at an isodose line that encompassed the primary tumor and regional lymph nodes. All patients were treated with the 3-or 4-field technique. Twenty-six patients were treated with preoperative radiotherapy using 4500 cGy with a 3-field boost to 5040 cGy. One patient was treated to 4860 cGy, and four were treated to 4500 cGy. Postoperative patients were treated to various doses. One patient was treated to 5040 cGy, one patient to 5300 cGy, two patients to 5580 cGy, and one patient to 5940 cGy.
One patient, who chose to stop her radiotherapy treatment, received 3240 cGy.
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Concomitant chemotherapy was given to 26 of 32 preoperative patients during radiotherapy treatment. Twenty-three patients were treated with fluorouracil (5FU) by continuous infusion (although two did not complete 5FU due to complications), three were treated with capecitabine.
Two of the six postoperative radiotherapy patients were treated with 5 FU.
For patients who had preoperative radiotherapy, TAE was performed on average 48 days after completing radiation therapy (range, 28 to 87 days). The primary factors related to variability in surgical timing were patient tolerance and willingness to undergo surgical resection.
Postoperative radiotherapy was started a median 32 days after surgery (range, 27 to 48 days).
This range was less variable due to overall rapid and consistent recovery from the minimally invasive surgical TAR procedure. Close margins were defined as those closer than 5 mm of the inked margin. There were no instances of residual positive surgical margins on final pathologic review. Surgical technique has been described in a previous publication. 8 Study endpoints included local control, distant metastasis, cause-specific survival, and toxicity.
Additionally, the prognostic value of both complete pathological response and clinical staging through EUS ultrasound was examined. Toxicity was measured by both the Radiation Therapy
Oncology Group guidelines and the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. 9 Radiation complications were most often found in the visits immediately following the completion of radiation, but any side effect that could reasonably be attributed to radiation was coded.
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All statistical computations were achieved with SAS software (SAS Institute, Cary, NC). The Kaplan-Meier product-limit method was used to estimate freedom from specified endpoints.
10
The log-rank test statistic was used to detect significant differences in these endpoints between strata of selected prognostic factors.
Results
Patients and tumor characteristics are described in Local-regional control was achieved in all of the postoperative patients and in 28 of the 32 preoperative patients (88%). Four patients had an initial local recurrence. Three out of four of the patients with a local recurrence were staged clinically as T3 by EUS, and the other patient with a local recurrence did not have an EUS for pretreatment staging. One of the four patients who recurred underwent palliative fulguration due to age and previous development of a metastasis.
The other three patients were salvaged with APR, and one eventually developed a metastasis. In addition to those with a local recurrence, three other patients underwent eventual APR or lower anterior resection (LAR). One postoperative patient had an APR after refusing to continue with
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Overall and cause-specific survival rates at 5 years were 79% and 91%, respectively. 17 performed a meta-analysis of 42 studies to determine the pooled sensitivity and specificity of EUS. The sensitivity and specificity to identify T stage for these cancers was above 85% for T1-3 stage rectal cancer. 17 In our series, we found that EUS staging was predictive of local failure, but not distant metastasis. The accuracy of EUS allows patients with early-stage rectal cancer to be identified and the possibility of increased risk for local recurrence associated with T2 or greater stage after transanal endoscopic microsurgery to be more thoroughly evaluated and reconsidered.
Tumor size, distance from the anal verge, and histological characteristics are important prognostic variables when considering a patient for TAE. In a prospective randomized trial of 70 patients with rectal cancer treated for T2N0 lesions, Lezoche et al 4, 5 found that total mesorectal excision and TAE with preoperative chemoradiation resulted in similar outcomes at the patients' 5-year followup. In this study, the patients selected had tumors located within 6 cm of the anal verge, with diameters <3 cm, and of well-or moderately differentiated histology. Also, patients with neural, vessel, or lymphatic invasion were excluded. Thus, the study showed that patients with favorable tumor characteristics can have a TAE without worsening their outcomes. Clinical and pathological response to radiotherapy can be used as a prognostic tool to identify patients who are at higher risk for distant and local failure. Guerrieri et al 3 showed, in a study of 196 patients with T1 to T3 rectal cancer, that TAE with preoperative radiotherapy results in similar survival and local recurrence outcomes when compared to transanal endoscopic microsurgery outcomes found in the literature. 3 The study also showed that patients who respond either clinically or pathologically to preoperative therapy tend to do well. They found no local recurrences or distant metastases for any downstaged or downsized tumors, suggesting that response to therapy is prognostic in patients who have had TAE.
Treatment decisions can be reasonably based on clinical or pathological response to therapy due to its prognostic value. Nair et al 18 conducted a study where patients who had preoperative chemoradiotherapy followed by transanal excision were offered more extensive surgery (APR or LAR) if they did not have a complete pathological response. The goal of this treatment regimen is to treat patients who tend to do poorly more aggressively. They found that overall 5-year survival rates for patients with T2/T3N0 and T2/T3N1 lesions were 84% and 81%, respectively, which are similar to historic controls. 18 Using tumor markers to predict recurrence rates is a promising way to determine which patients would be good candidates for TAE. More large randomized studies with well-defined selection criteria are needed to examine the question of whether TAE combined with preoperative chemoradiotherapy is an equivalent treatment to traditional therapy. There are currently no large randomized studies evaluating this issue. However, NCCN ACOSOG Z 6041 is a phase II trial in which rectal cancer patients undergo high-dose external-beam radiotherapy and receive oral capecitabine and oxaliplatin followed by TAE for T2N0 lesions. The goal is to enroll 100 patients, and it is due to finish in 2014. Although not randomized, it will be the largest study in the United States evaluating the use of TAE with preoperative chemoradiotherapy for T2N0 lesions. If this study shows promising results, it may promote further studies and the eventual change of NCCN guidelines.
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Conclusion
Our analysis shows that patients with early-stage rectal lesions who undergo preoperative or postoperative radiation and TAE have similar survival outcomes to similar patients in the published results who undergo abdominal resection. Local recurrence was higher for patients with T3 lesions when compared to historic controls, and these patients should be considered for total mesorectal excision. Complications from TAE are less morbid than the comparable radical surgery. Complete pathological response and downstaging were not statistically significant predictive clinicopathologic features, although the small sample size combined with good overall survival rates makes it difficult to achieve statistical significance. Given our survival endpoints, TAE is a reasonable option when the patient is unwilling or unable to tolerate the morbidity associated with traditional transabdominal surgery. Figure   Figure 1 . Local control rates for all patients with endoscopic ultrasound staging.
